Honorary Membership
Honorary Membership is ECNP’s highest distinction. It is awarded to ECNP members who have made outstanding contributions to the field and the College over a lifetime of exceptional service.
| Members |
| Jules Angst, Switzerland (1926- ), admitted 1999 Emeritus professor of psychiatry, University of Zurich |
| Herman M. van Praag, The Netherlands (1929- ), admitted 2007 Emeritus professor of psychiatry and neuropsychology, University of Maastricht Winner of the 1995 ECNP Neuropsychopharmacology Award |
| Stuart A. Montgomery, United Kingdom (1938- ), admitted 2010 Emeritus professor of psychiatry, Imperial College London Winner of the 1999 ECNP Neuropsychopharmacology Award |
| Jan M. van Ree, The Netherlands (1945- ), admitted 2010 Emeritus professor of psychopharmacology, University of Utrecht Officer of the Order of Orange-Nassau |
| Joseph Zohar, Israel (1948- ), admitted 2023 Professor of psychiatry at Tel Aviv University, Israel |
| Alec Coppen, United Kingdom † (1923-2019), admitted 1996 Formerly of the Neuropsychiatric Research Unit , Medical Research Council, Epsom Winner of the 1991 ECNP Neuropsychopharmacology Award |
| Paul A. J. Janssen, Belgium † (1926-2003), admitted 1999 Founder of Janssen Pharmaceutica and the Janssen Research Foundation |
| Hanns Hippius, Germany † (1925-2021), admitted 2001 Emeritus professor of psychiatry, University of Munich Winner of the 1997 ECNP Neuropsychopharmacology Award |
| Arvid Carlsson, Sweden † (1923-2018), admitted 2002 Emeritus professor of pharmacology, University of Gothenburg Winner, with Paul Greengard and Eric Kandel, of the 2000 Nobel Prize for Medicine |
Fellow Membership
ECNP Fellows are appointed by the Executive Committee (EC), in recognition of scientific distinction and notable contributions to the College.
Fellow Membership recognises the achievements of distinguished ordinary members, both as researchers and as contributors to the College’s mission.
ECNP Fellow Members
Please view more info about a Fellow member by clicking on the name.
| Members | Areas of interest | |
| Roger Adan | Eating disorders, gene therapy, brain-gut-microbiome axis, pharmacological interventions, animal models, genetic and molecular approaches. | |
| David Baldwin | Anxiety disorders, anxiolytics, mood disorders, antidepressants. | |
| Josefina Castro-Fornieles | Psychotic disorders and eating disorders. | |
| Eero Castrén | Neuronal plasticity, neurotrophic factors, antidepressants. | |
| Roberto Cavallaro | Schizophrenia: clinical, neuroleptics and antipsychotics: clinical, cognitive enhancing drugs, drug monitoring, extrapyramidal syndrome, genetics/molecular genetics, molecular neurobiology, memory and cognitive disorders. | |
| Philip J Cowen | Psychopharmacology of mood disorders. | |
| Suzanne L. Dickson | Eating disorders, obesity, nutritional psychiatry, feeding behaviours, gut-brain signalling, chemogenetics and circuit mapping. | |
| Katharina Domschke | Anxiety and anxiety disorders, mood disorders. | |
| Haim Einat | Biological rhythms; circadian rhythms and the consequences of disruption of circadian rhythms in health and disease; chronotypes; chronotherapy. | |
| Naomi Fineberg | Obsessive-compulsive disorders, anxiety disorders, biological markers, biological rhythms, diagnosis and classification. | |
| Guy Goodwin | Antidepressants: clinical, anxiety, bipolar disorders, depression: clinical, lithium and other mood stabilisers. | |
| Lucianne Groenink | Behavioural pharmacology, anxiety, stress, psychoneuroendocrinology, serotonin, GABA, antipsychotics. | |
| Catherine J Harmer | Mood disorders, pharmacological interventions, psychotherapy, neuropsychology, neuroimaging. | |
| Jaanus Harro | Animal models, antidepressants: basic, anxiety, behavioural pharmacology, depression: basic, drug dependence and abuse: basic, drug dependence and abuse: clinical, genetics/molecular genetics, neuropeptides, stress. | |
| Martien Kas | Neurobiology of behaviour, translational neuroscience, transdiagnostic approaches, digital phenotyping, linking neuropsychiatry to quantitative biology, social functioning, sensory processing. | |
| Siegfried Kasper | Alzheimer’s disease: clinical, antidepressants: basic, antidepressants: clinical, anxiety, anxiety disorders, biological rhythms, bipolar disorders, brain imaging, depression: basic, depression: clinical, neuroimaging: functional, neuroleptics and antipsychotics: clinical, neuropharmacology, panic disorders, receptors, schizophrenia: clinical, serotonin. | |
| Gitte M. Knudsen | Brain imaging, neuropharmacology, other neurotransmitters, pharmacokinetics, receptors, neuroimaging, functional, and structural neuroimaging. neurology: clinical, depression: clinical. | |
| Stefan Leucht | Psychotic disorders, pharmacological interventions, psychotherapy, biostatistics and computational methods, pharmacology. | |
| Klaus-Peter Lesch | Molecular neurobiology of cognitive control and self-regulation, epigenetics of brain development and neuronal plasticity, imaging genetics, animal models of attention, cognition, and learning/memory, pathogenetic mechanisms of attention-deficit/hyperactivity, substance use and co-morbid disorders. | |
| Astrid Linthorst | The effects of stress on brain function and physiology; the role of stress in mental health and disease; impact of lifestyle on stress coping and stress resilience. Improving attainment, student resilience, and employability through advanced curriculum and assessment design. |
|
| Paul J. Lucassen | Neurogenesis, stress, neuroendocrinology, Alzheimer's disease: basic, depression: basic. | |
| Hamish McAllister-Williams | Antidepressants: clinical, biological markers, bipolar disorder, brain Imaging, depression: clinical, ECS-ECT, lithium and lithium and other mood stabilisers, memory and cognitive disorders, neurophysiology: clinical, neurosteroids, psychoneuroendocrinology, serotonin, stress. | |
| Andreas Meyer-Lindenberg | Genetics/molecular genetics; environmental risk factors; neuroimaging: functional, neuroimaging: structural, neuropeptides, schizophrenia: basic, schizophrenia: clinical, transgenic models. | |
| Luisa Minghetti | Alzheimer's disease: basic, biological markers, calcium, cell culture, glia, molecular neurobiology, neuroimmunology, neuroprotection. | |
| David Nutt | Addiction, alcoholism, opiates, PET imaging, MRI imaging, psychopharmacology, psychedelics, MDMA, cannabis, GABA, 5HT, dopamine, noradrenaline. | |
| Stefano Pallanti | Anxiety disorders, obsessive-compulsive disorders, ADHD, depression, neuroimmunology, neuromodulation, pharmacology: clinical. | |
| Andreas Reif | Precision psychiatry and biomarkers, bipolar disorder, therapy-resistant depression, suicide prevention, adult ADHD. | |
| Janusz Rybakowski | Antidepressants-clinical, bipolar disorders, depression: basic, clinical; lithium and other mood stabilisers, neuroleptics and antipsychotics: clinical, obsessive-compulsive disorders, psychoneuroendocrinology, psychoneuroimmunology, schizophrenia: basic, clinical; genetics/molecular genetics. | |
| Koen Schruers | Anxiety, fear (learning), panic, trauma, OCD, invasive and non-invasive brain stimulation, psychopharmacology, experimental models of psychopathology, biological mechanisms of psychological therapy. | |
| David Slattery | Animal models, behavioural pharmacology, neuropharmacology, neuropeptides, psychoneuroendocrinology | |
| Jari Tiihonen | Aggression: clinical, brain imaging, drug dependence and abuse: clinical, epidemiology, genetics/molecular genetics, neuroleptics and antipsychotics: clinical; schizophrenia: clinical. | |
| Nic J.A. van der Wee | Brain imaging, anxiety disorders, depression, obsessive-compulsive disorders, stress, anxiety, epidemiology, behavioral pharmacology. | |
| Eric Vermetten | Anxiety disorders, anxiety, stress, neuroimaging, structural, neuroimaging, functional, biological markers, psychoneuroendocrinology, sleep disorders, molecular neurobiology. | |
| Gil Zalsman | Depression basic, depression clinical, childhood disorders, genetics. |
To be eligible for Fellow Membership, an ECNP ordinary member must fulfil five out of six of the following criteria:
1
Have attended at least three ECNP Congresses in the last five years
2
Have presented at one ECNP Congress in the last ten years
3
Be a reviewer in good standing for European Neuropsychopharmacology
4
Have served on an ECNP Committee, or volunteered to serve
5
Have been active in organising an ECNP activity or have been an active member of an ECNP Network
6
Have supervised or mentored research projects
Conferral of Fellow Membership is at the ultimate discretion of the Executive Committee.
The role of the Fellow is to be actively engaged in the College, by sitting on committees, participating in ECNP Networks, be involved in ECNP activities, and act as host for Research Internships etc.
If you meet the above criteria and want to become a Fellow Member, you are requested to send a motivation letter, including CV, to secretariat@ecnp.eu.
Your application will be reviewed by the Executive Committee during their next meeting.